able for truncal obesity and no hepatosplenomegaly or vascular bruits. He had intact sensation and motor function of all four extremities as well as normal deep tendon reflexes.
. Relationships among systemic, glomerular capillary, and peritubular capillary pressures. The glomeruli and peritubular capillaries operate at lower pressures than systemic pressure; consequently, adequate autoregulation of blood flow must occur to "step down" systemic pressure. Autoregulation is primarily governed by either myogenic responses of the afferent arteriole or by tubuloglomerular feedback mechanisms (stimulated by adenosine, angiotensin II and renal sympathetic nerve activity, and inhibited by nitric oxide). Failure of autoregulation either due to myogenic reflex dysfunction secondary to vascular disease, or tubuloglomerular feedback dysfunction from diabetes due to excess nitric oxide production may result in glomerular capillary hypertension and injury.
for delaying progression of renal and cardiovascular dischanical injury to the delicate glomerular capillary vessels. Should glomerular capillary perfusion fall below the ease in the patient with incipient nephropathy.
autoregulatory threshold of approximately 60 mm Hg Risk factors because of systemic hypotension, then increasing activation of the RAAS enhances efferent glomerular arterioMultiple risk factors affect the development of cardiolar vasoconstriction and facilitates maintenance of glovascular disease and progression of renal disease in merular capillary pressure in a range that is necessary patients with early renal insufficiency. These include for filtration [6] . non-modifiable risk factors such as genetics, but more Adequacy of control of glomerular capillary pressure important, they include modifiable risk factors such as is likely one of the most important factors in reducing glycemic control, dietary protein and salt intake, blood pressure, dyslipidemia, hyperhomocystinemia, proteinrisk for progression of renal injury ( Fig. 1) . Control of uria, and cigarette smoking [1] [2] [3] . For the sake of clarity glomerular capillary pressure works well within the norand brevity, I will focus here on factors related to blood mal autoregulatory range of the kidney (60-150 mm Hg) pressure and proteinuria both as interdependent and [4] [5] [6] [7] . Patients with pressures exceeding 150 mm Hg, or independent modifiable risk factors for progression of patients with damage to the autoregulation capacity of renal insufficiency and ultimately cardiovascular disease.
the afferent glomerular arterioles (as can occur in a patient with diabetes and vascular disease or who ingests Renal autoregulation a high-protein diet) can be vulnerable to injury from levels of systemic blood pressure within the so-called Renal autoregulation is the physiologic mechanism whereby glomerular capillary pressure varies by only "normotensive" range (125-140 mm Hg). This level of blood pressure exceeds the usual range of pressures in about 5 mm Hg over a wide range (60 to 150 mm Hg) of alterations in the renal perfusion pressure. Increasing the glomeruli and therefore can cause glomerular capillary hypertension in patients with damaged autoregulasystemic blood pressure induces a myogenic reflex that stimulates smooth muscle cells in the afferent glomerular tory capacity. These circumstances, coupled with the increased vasodilation of the afferent glomerular arteriole arterioles to initiate a reflex contraction that reduces renal blood flow [4] . A second mechanism that facilitates in diabetes mellitus [8] , markedly increase glomerular capillary pressure and the risk for injury. The increasing preglomerular vasoconstriction is the increased delivery of sodium chloride to the distal nephron, which stimupressure can result in mechanical stretch and strain within the delicate glomerular capillary vascular beds lates a tubuloglomerular feedback mechanism that causes afferent arteriolar vasoconstriction [4, 5] . As a conseand mesangial cells; this stress in turn results in an injury and repair response largely mediated by fibrogenic cytoquence of these two mechanisms, autoregulation of glomerular capillary pressure is carefully maintained within kines and angiotensin II [9] . Repetitive injury results in scarring, inflammation, and glomerulosclerosis and a tight range, thereby assuring stable glomerular filtration while simultaneously reducing the likelihood of meultimately leads to loss of renal function. Subsequent loss
The Modification of Diet in Renal Disease (MDRD) study demonstrated important benefits of rigorous control of blood pressure in patients with non-diabetic renal disease and proteinuria (Fig. 2) [11, 15] . The proteinuric patients (defined as patients with Ͼ1 g of proteinuria/ day) demonstrated substantial benefits with better blood pressure control (125/75 mm Hg), perhaps because the proteinuria was a reflection, in part, of impaired renal autoregulation and glomerular capillary hypertension. Bakris demonstrated a nearly linear relationship between systolic blood pressure achieved with pharmacotherapy and rate of loss of renal function each year in an evaluation of non-diabetic patients and diabetic patients, both groups with renal disease [16] . Likewise, Jafar et al noted an increased risk for doubling of serum creatinine or reaching end-stage renal disease in a meta-analysis of patients with non-diabetic renal disease as a function of systolic blood pressure achieved with pharmacotherapy [17] . These and other clinical observations have provided important insights for establishing goals for optimal levels of blood pressure in patients with renal disease.
These analyses also have indicated that an average of 3 to 4 medications (or more) are needed to achieve lower, more intensive blood pressure control (125-130 mm Hg systolic) in patients with renal disease. However, these studies have not provided insight as to how early in the less than 130/80 mm Hg), the greater the likelihood of preventing progressive renal injury (as a reflection of preventing progression from microalbuminuria to clinical proteinuria). Needless to say, blood pressure is more of nephrons results in the development of glomerular capillary hypertension in residual nephron units, conseeasily controlled with less medication when the untreated systolic blood pressure is 130-140 mm Hg. Possibly, earquently exposing them to further mechanical injury [10] . This series of sequential events ultimately leads to prolier treatment will prevent the need for more medication in subsequent years. This hypothesis is an important gressive renal insufficiency. Consequently, patients with incipient nephropathy might require levels of systemic consideration that needs to be tested in clinical trials. blood pressure below what we have traditionally targeted Proteinuria and renal injury in order to reduce the risk for progressive renal injury.
Evidence from clinical trials indicates that proteinuria Blood pressure and renal injury is an independent predictor of progression of renal disease [15, 18, 19] . The severity of baseline proteinuria is The kidney's ability to regulate glomerular pressure is important for prevention of renal injury. Rigorous an important predictor, not only of the rate, but also of the likelihood, of loss of renal function [15, 17] . Clinical control of both systemic and glomerular capillary blood pressure is needed, particularly in patients with certain trials also have demonstrated that the reduction in protein excretion with antihypertensive agents or dietary diseases, such as diabetes, that can predispose to impaired renal autoregulation. Abundant clinical data indiprotein restriction correlates directly with the reduction of the rate of loss of renal function [20, 21] . Newer clinical cate that the net level of blood pressure achieved with antihypertensive therapy is predictive of risk for losing trials indicate that the net reduction in proteinuria achieved with antihypertensive therapy ultimately prerenal function both in non-diabetic patients and diabetic patients with renal disease [11] [12] [13] [14] .
dicts the rate of loss of renal function over time; the initial severity of baseline proteinuria does not [19, 22] . as it results in increased glomerular permeability to proteins and, at the same time, greater mechanical stretch These observations indicate that proteinuria is a modifiable risk factor of progressive renal disease. However, and strain within the glomeruli and surrounding mesangial cells. This process results in greater production of in clinical practice, attempting to reduce or abolish proteinuria is not common, as more emphasis has been angiotensin II, transforming growth factor-␤1, and a subsequent increase in collagen synthesis [9, 26] . Conseplaced on reducing blood pressure.
Microalbuminuria is an important predictor of subsequently, both glomerular hyperfiltration and excessive tubular reabsorption of proteins are likely additional quent risk for nephropathy in both type 1 and type 2 diabetes [23] [24] [25] . Its presence also is predictive of cardiocauses of renal injury. The reduction of proteinuria is important in patients vascular mortality in diabetic and non-diabetic patients [23] [24] [25] . Microalbuminuria likely reflects evidence of a both with non-diabetic and diabetic renal disease. The Ramipril Efficacy in Nephropathy (REIN) study was in systemic vasculopathy, with damage to the glomerular vascular bed being one of the first areas of damage that part designed to assess the relationship between proteinuria and progression of renal disease in non-diabetic is clinically evident. Microalbuminuria also can represent evidence of glomerular capillary hypertension and hyppatients. Investigators noted that the mean rate in decline in GFR of the patients whose urinary protein excreerfiltration, perhaps due to loss of afferent glomerular arteriolar vasoconstriction and dysfunctional autoregulation was between 1 and 3 g/day was one-third that of the patients whose urinary protein excretion was greater tion of glomerular capillary blood pressure. Thus, the presence of microalbuminuria, like proteinuria, indicates than 3 g/day [18] . Moreover, this study also noted that the use of the ACE inhibitor ramipril was the only timethe patient with a greater risk of developing both progression of renal disease and cardiovascular events. dependent variable that predicted the slower rate in decline of GFR. The report thus concluded that renal proExcessive proteins filtered by the glomerulus lead to an increase in both renal tubular cell reabsorption of tection was linked to a reduction in urinary protein excretion and not blood pressure. proteins and overall protein catabolism. Remuzzi and Bertani have suggested that excessive renal tubular cell Jafar et al conducted a meta-analysis of 1860 patients enrolled in 11 randomized controlled trials comparing reabsorption of proteins activates vasoactive and inflammatory genes, thereby resulting in the synthesis and the effects of multidrug antihypertensive regimens, including or not including ACE inhibitors, on the progression elaboration of several substances within the interstitium. These substances in turn result in fibrogenesis, collagen of non-diabetic renal disease [17] . They demonstrated that the level of proteinuria achieved with pharmacotherproduction, and scarring ( Fig. 3) [26]. Glomerular capillary hypertension would likely accelerate this process, apy was predictive of the rate of loss of renal function.
This finding indicated that urinary protein excretion was These results are in concert with the observation by the Collaborative Study Group of the advantages of the a modifiable risk factor for the progression of renal disease. It is interesting that they also noted that the benefi-ACE inhibitor captopril versus conventional therapy in preventing renal insufficiency in type-1 diabetes [27] . cial effect of ACE inhibitors in retarding progression of renal disease remained significant, even after they However, similar conclusive data showing nephroprotection are not available with ACE inhibitors in proteinuric controlled for the level of urinary protein excretion achieved.
type 2 diabetic patients with incipient nephropathy. Two placebo-controlled studies indicated that ACE The Collaborative Study Group demonstrated that only patients with type 1 diabetes who achieved at least inhibitors could prevent the progression of microalbuminuria to macroproteinuria in "normotensive" (systolic a 50% reduction in urinary protein excretion derived benefit, defined as subsequent stabilization of renal func-125-130 mm Hg) type-1 and type-2 diabetic patients [35, 36] . In both studies, modest but significant reductions tion [27] . This study indicated that intensive antiproteinuric strategy, concurrent with an optimal blood pressure in blood pressure occurred with ACE inhibitor therapy. Consequently, one cannot be sure whether the prevenstrategy, is important in reducing the likelihood of progressive nephropathy in type 1 diabetics. Information tion of macroproteinuria is simply a blood pressure effect, a unique effect of the ACE inhibitor, or both. These regarding the importance of reducing proteinuria on the rate of progression of renal disease in patients with type-2 studies also indicated that earlier therapeutic intervention, even with treatment of blood pressure in the "nordiabetes is inconsistent, in large part because of the small size and short duration of the studies to date (abstract; motensive" range, could prevent the development of macroproteinuria. Unfortunately, there are fewer than 400 patients in all six Lower blood pressure goals in the presence of microalbuminuria or proteinuria are important considerations studies combined. Only one of these six studies showed significant differences between the decline in GFR in for treatment. Reaching the desired systolic blood pressure goal frequently requires one drug for every 10 patients treated with or without ACE inhibitors [28] . Thus, one can only extrapolate the benefits of an ACE mm Hg of systolic blood pressure reduction. The presence of microalbuminuria or proteinuria requires specific inhibitor in proteinuric patients with type 2 diabetes based on experience in type 1 diabetic patients or patherapy including drugs that block the renin-angiotensin system, non-dihydropyridine calcium channel blockers, tients with non-diabetic renal disease. Whether the benefits of ACE inhibitors in preventing and restriction of dietary sodium and protein. Proteinuria and hypertension are separate and independent yet or protecting against worsening of renal disease can be generalized to other classes of drugs that block the reninintertwined modifiable risk factors for progression of renal insufficiency.
angiotensin system can now be addressed with the results of two recently completed trials. The RENAAL and Angiotensin-converting-enzyme (ACE) inhibitors attenuate the rate of progression of renal disease both in IDNT trials provide evidence that an angiotensin II type-1 receptor blocker protects against the progression type 1 diabetics [13, 26] and patients with non-diabetic renal disease [17] . The benefit of ACE inhibitors likely of renal disease in type 2 diabetics, independent of blood pressure effects [33, 34] . Both these studies demonstrated is derived from antihypertensive/antiproteinuric properties and the anti-mitogenic/anti-fibrogenic effects of anstatistically significant risk reduction for doubling of serum creatinine, end-stage renal disease (ESRD), and giotensin II antagonism [9] . The meta-analysis by Jafar et al demonstrated the important benefit of ACE inhibideath (the primary composite end point of the trials) compared to traditional (diuretic, beta blocker, vasodilators in patients with non-diabetic renal disease [17] . tor, etc.) or calcium channel blocker-based therapy.
progressive renal failure have not been performed. However, if their benefits are tied primarily to blood pressure Moreover, both studies demonstrated a consistent antiproteinuric effect of the angiotensin II type-1 receptor and proteinuria reduction, then it is likely that the two classes of drugs would be similar given their similar effiblocker. Although not analyzed yet, it is likely that, as in the study with captopril in type-1 diabetics [27] , the cacy in short-term clinical trials. The clinical data with drugs that block the renin-angioanti-proteinuric effect of the angiotensin II receptor blockers losartan (RENAAL) and irbesartan (IDNT) tensin system support the pathophysiologic construct linking glomerular capillary hypertension, proteinuria, will correlate with their nephroprotective properties. The Irbesartan Microalbuminuria Trial (IRMA-2), which was and risk for progression of renal disease [10] . It is not known whether an ACE inhibitor and an angiotensin II conducted in hypertensive microalbuminuric patients with type-2 diabetes, demonstrated that an angiotensin type-1 receptor blocker given together provide greater protection against progressive loss of renal function than II type-1 receptor blocker could prevent the development of clinical proteinuria when compared with tradiadministration of either agent alone. Some clinical studies indicate that an ACE inhibitor and angiotensin II tional antihypertensive therapy, despite similar reductions in blood pressure [38] .
type-1 receptor blocker together provide more effective blood pressure reduction [39] and near additive antiAs a result of these newer trials, it appears that ACE inhibitors as well as angiotensin II type-1 receptor blockproteinuric effects [40] . ers retard progression of renal disease compared with Relationship between renal disease progression and other therapies. The evidence supporting ACE inhibitors cardiovascular disease is in patients with type-1 diabetes and non-diabetic renal disease, while the evidence supporting the use of the Preventing progression of renal disease is an important strategy in reducing the risk for cardiovascular events. angiotensin II type-1 receptor blockers is in patients with type-2 diabetes. The rationale supporting the use of these Patients with renal insufficiency, especially those with ESRD, have a markedly increased risk for cardiovascular drugs relates in part to their more consistent antihypertensive and antiproteinuric effects relative to other antievents (Fig. 4) [41] . This cardiovascular risk is especially substantial in diabetics, who also have a higher mortality hypertensive drugs. In addition, antihypertensive-and anti-proteinuric-independent benefits are likely associrate if they are on dialysis or have had a transplant [42, 43] . In the IDNT trial, nearly 25% of the type-2 ated with these therapies [17] . Clinical trials comparing the two therapies with regard to reducing the risk of diabetic patients had a doubling of the serum creatinine.
Of those patients with doubled serum creatinine, 50% Dr. Madias: Despite reaching target blood pressure, many patients with renal disease continue to have sigunderwent dialysis within one year, and 25% were dead within three years. Consequently, any strategy that is nificant proteinuria. Could you comment on additional strategies for controlling proteinuria, such as using effective in preventing a doubling of serum creatinine also will likely be beneficial in reducing the risk of cardio-"mega doses" of ACE inhibitors, combining ACE inhibitors with angiotensin II type 1 receptor antagonists, and vascular events. the use of aldosterone antagonists? Summary Dr. Weir: The use of large or "mega" doses of ACE inhibitors is a fascinating area. In general, clinicians, Let me summarize. I argue that optimal strategies to provide more effective prevention or protection against and even many nephrologists, are concerned about using higher doses of ACE inhibitors, even doses in the aprenal disease progression should focus on earlier and more intensive blood pressure reduction, proteinuria reproved dosing range, let alone "mega" doses. This is particularly true in patients who have early evidence of duction (preferably eliminated), and renin-angiotensinaldosterone system pharmacologic blockade. These are renal disease (serum creatinine, 1.4-2.0 mg/dL) despite demonstrated efficacy and safety of these drugs in clinical modifiable risk factors for development of progressive renal insufficiency. I believe that the weight of medical trials. Small studies have shown that titrating ACE inhibitors to higher doses can effectively reduce proteinuria evidence supports the need for earlier and more intensive efforts to control blood pressure below traditionally ac- [44] . This is also a function of higher doses providing more effective reduction in blood pressure. Adding an ceptable levels (less than 130/80 mm Hg), particularly if evidence of microalbuminuria or proteinuria is present.
angiotensin II receptor blocker, thiazide diuretics, or a non-dihydropyridine calcium antagonist also can someWe need to identify patients at risk earlier, use a relatively large number of drugs to achieve our goals, and times potentiate the antiproteinuric effects of ACE inhibitors. Several small clinical trials have indicated the better educate the public and clinicians of the need for earlier, more rigorous efforts for the control of all risk benefit of this strategy (abstract; Hemmelder et al, J Am Soc Nephrol 6:420, 1995) [40, 45] . Again, how much factors. Efforts at encouraging a healthier lifestyle by reducing smoking, reducing a high-salt and high-satuthe further reduction in blood pressure plays a role in decreasing proteinuria remains open to question. Also rated-fat diet, and by increasing the frequency of exercise can help reduce cardiovascular risk and improve the not resolved is the mechanism of incremental reduction of proteinuria: are there specific effects on the glomeruefficacy of antihypertensive, antiproteinuric medications. lar basement membrane, or are the additive effects of QUESTIONS AND ANSWERS these specific drugs purely related to reducing systemic and glomerular capillary pressure? Dr. Nicolaos E. Madias (Executive Academic Dean, Tufts University School of Medicine, Boston, MassachuPerhaps more demanding of our attention is the clinical importance of modifying dietary salt consumption. setts): You indicated that for certain groups with renal disease, a lower target for blood pressure control might
The scientific literature clearly indicates that the antiproteinuric and antihypertensive effects of all drugs are comapply, that is, lower might be better than low. Could you give us more specific recommendations about target promised by increasing dietary salt consumption (even in the physiologic range) [46] [47] [48] . Consequently, efforts blood pressures for a range of groups within the renal disease population?
at modifying salt consumption should always be part of every antiproteinuric strategy. Whether adding a thiaDr. Weir: I can give you some of my own thoughts, but I can't back them up with any data, because clinical zide diuretic, or another drug like an angiotensin II receptor blocker, or using higher doses of ACE inhibitors trials have not been completed that pursued either systolic blood pressure below 125 mm Hg or specific treator angiotensin II receptor blockers would render the patient more tolerant to the hypertensive and proteinuric ment for extinguishing proteinuria or albuminuria. With regard to the patient with chronic renal insufficiency effects of higher dietary salt intake needs to be tested in clinical trials. Perhaps this is another reason why higher with either the presence of micro-or macroalbuminuria/ proteinuria, my clinical efforts are geared toward at least doses of ACE inhibitors and angiotensin II receptor blockers (in the approved dosing range, or possibly getting the systolic pressure into the 120s and extinguishing the proteinuria or albuminuria. If I am unsuccessful in above) need to be considered in clinical practice as part of a strategy for facilitating better reduction in both attaining those two goals, then I continue to add specific mediations to further lower the systolic pressure and blood pressure and proteinuria. Modifying dietary protein intake also might help reduce proteinuria, but it extinguish the proteinuria, much in the same way that a cardiologist would advance ACE inhibition to reach raises concern about adequacy of nutrition and requires expert nutritional counseling. doses demonstrated to be effective in the risk reduction trials in heart failure.
Another area of interest is the pharmacologic block-ade of aldosterone. Some small clinical studies indicate progression of vascular disease. Large-scale clinical trials, such as the Heart Outcomes Prevention Evaluation that aldosterone blockade and ACE inhibition have additive antiproteinuric effects (abstract; Epstein et al, Am (HOPE), have shown unequivocal benefit of lower blood pressure and blocking the RAAS [37] . Other clinical J Coll Cardiol 39(Suppl 4): 249A, 2002). This information needs to be substantiated in future clinical trials. trials in patients with cardiac or renal disease demonstrated similar, consistent benefits with better blood presDr. Madias: Although we have been using ACE inhibitors for many years, it might well be that we are far sure control and blocking of the RAAS [37, 49] . Dr. James Strom (Division of Nephrology, St. Elizafrom knowing how to use them optimally. We tend to use virtually the same doses for a very wide range of clinbeth's Medical Center, Brighton, MA): One of the confounding features of the evaluation of proteinuria in an ical settings-asymptomatic hypertension, hypertension with left-ventricular hypertrophy, congestive heart failindividual is the potential for "structural" protein loss.
We all follow patients with class-IV lupus nephritis in ure, diabetic microalbuminuria, overt diabetic nephropathy, and advanced renal disease. We might find that whom one doesn't really believe the proteinuria is due to hyperfiltration. Patients like this might have a combiwidely different doses of ACE inhibitors are required for optimal response in various clinical settings.
nation of factors causing heavy proteinuria despite controlled systolic pressure. How would you advise proceedDr. Weir: Your point is excellent. All the dosing ranges have been driven by clinical trials focusing on ing in such a situation? Dr. Weir: Your question raises the issues of the relablood pressure reduction. There might be other clinical disease states that require different dosing strategies. As tive contribution of glomerular capillary pressure elevation and glomerular structural injury to proteinuria, and I mentioned earlier, in patients with systolic heart failure, higher doses of ACE inhibitors than necessary to imthe most effective way to treat it. I would submit that the lower the glomerular capillary pressure, the less the prove circulatory hemodynamics have demonstrated reductions in cardiovascular morbidity and mortality [49] .
hydraulic force of transglomerular passage of proteins. In a patient with glomerulonephritis and nephrotic-range Dr. John T. Harrington (Dean, Tufts University School of Medicine): What's the evidence in humans proteinuria, I would employ more rigorous efforts to drive that systolic blood pressure down as low as comfortthat proteinuria means an abnormality in glomerular capillary pressure regulation? Second, how much of the ably possible (to avoid presyncope) with drugs that block the RAAS. effect of angiotensin II blockade is hemodynamic, and how much is a nonhemodynamic effect? You spoke about how we can use proteinuria as a surrogate marker to titrate blood pressure to ideal levels. the presence of glomerular capillary hypertension. I am suspicious that it indicates either vasculopathy, inadeHowever, some of our clinic patients who have chronic renal disease do not exhibit proteinuria. What surrogate quate renal autoregulation, or possibly both. How to quantify the contribution of each for a given patient is markers would you use with these patients? Dr. Weir: We clearly need more effective means of not yet known. I mention this to alert the clinician that the presence of microalbuminuria suggests a need for determining which patients with renal disease are at risk for developing progressive renal disease and cardiovasbetter blood pressure control (to less than 130 mm Hg systolic) and a therapeutic strategy designed to extincular disease, particularly if they have minimal evidence of proteinuria. The NIDDK has just started an observaguish the microalbuminuria.
One important consideration as part of a therapeutic tional cohort study in patients with early renal insufficiency to look at biomarkers for progression of both strategy is blocking the activity of the RAAS. How is the RAAS involved in the development of vascular disrenal and cardiovascular disease. When completed, this trial should provide much relevant information. Our cenease? On one hand, the RAAS is well described as a neuroendocrine system that regulates circulatory hoter is evaluating different therapeutic strategies in renal transplant recipients with biopsy-proven chronic allomeostasis. But the RAAS also might have effector function in an autocrine or paracrine fashion by regulating graft nephropathy and low-grade proteinuria to determine the optimal level of blood pressure and specific vascular injury and repair responses, ultimately leading to remodeling and restructuring. From a clinical standbenefits of drugs that block the RAAS. This study provides measurements of renal function and renal histology point, there is an interrelationship between level of blood pressure with the resulting mechanical stretch and strain, with sequential renal biopsies during follow-up. The observations of this study also might provide important vascular risk factors, and progression of vascular injury. These observations might explain why rigorous control insights into the management of patients with other forms of renal disease. of blood pressure coupled with therapeutic strategies that block the RAAS have more success in slowing the Clinical trials to evaluate optimal strategies in patients with non-proteinuric renal disease will likely take longer Dr. Weir: It is likely that drugs that block the RAASrenal transplant. Patients will receive similarly effective pharmacotherapies to control blood pressure. The differthe ACE inhibitors and angiotensin II receptor blockers-have blood pressure-dependent and blood presence in outcome for patients on a drug that blocks the RAAS versus a non-RAAS-blocking drug will be comsure-independent benefits on slowing progression of renal disease in diabetics and non-diabetics. It will probapared on cardiovascular end points. As part of our efforts to design these two trials, we are also evaluating physibly take more patients or longer follow-up to demonstrate this in a single clinical trial, unless a properly cian use of drugs that block the RAAS in dialysis and transplant patients. There are some surprising differperformed meta-analysis of many clinical trials is done. We still do not know with certainty the mechanism of ences among health care providers. In general, the usage is quite low, particularly in patients with renal transaction of either the ACE inhibitors or the angiotensin II receptor blockers. Until we do, it is hard to predict plants.
Dr. John Gill (Research Fellow, Division of Nephrolthe long-term effects of these two therapeutic classes that block the RAAS.
ogy, New England Medical Center): In your previous comments, you alluded to the transplant population on Dr. Madias: We're increasingly learning about the cluster of genes that importantly influence susceptibility a couple of occasions. You suggested that we ignore the potential benefits of angiotensin II receptor antagonists to various chronic diseases. Could you talk about the genetic background of the individual in terms of the rate compared to ACE inhibitors. However, given the potential for complications, specifically hyperkalemia, if we of progression of renal disease and the response to ACE inhibition?
decide to use these medications, might angiotensin II receptor blockers be favored given their known ability Dr. Weir: I have not been overwhelmed with the available gene polymorphism data, particularly for the ACE to decrease TGF-␤? Dr. Weir: Good point. Whether ACE inhibitors or gene, to make them clinically relevant at the present time. This is particularly true in patients with nephropaangiotensin II blockers can more effectively reduce renal scarring, perhaps due to effects on angiotensin II or thy due to type 2 diabetes, the most common clinical form of renal disease.
TGF-␤, is unknown. Perhaps our current renal biopsy study in transplant patients will shed light on this subject. Dr. Harrington: Nick asked you earlier about the efficacy of the new aldosterone antagonists. Could you
The potassium issue is an important one, as it frequently is a stumbling block for physicians who want to prescribe tell us more about it?
Dr. Weir: Eplerenone is a new selective aldosterone ACE inhibitors or angiotensin II receptor blockers. These drugs do raise serum potassium on average 0.3 to receptor antagonist that does not have the endocrine side effects of spironolactone. Thus, it might allow the 0.5 mEq/L because of inhibition of aldosterone. One of the intriguing questions is whether it is healthier for you study of higher doses of the drug to evaluate effects not just on blood pressure, but also on vascular and target to have a potassium level of 5.5 to 6.0 mEq/L. That might be a more desirable potassium level in people with organ function. One congestive heart failure study that utilized 12.5 to 25 mg of spironolactone with an ACEcardiovascular risk factors. This possibility needs to be
